Locus Biosciences uses CRISPR-Cas3 technology to engineer phage therapeutics that destroy the DNA of target bacteria cells, including antibiotic-resistant superbugs, while leaving good bacteria unharmed. They are the exclusive global licensee of the foundational CRISPR-Cas3 patent estate and have acquired EpiBiome's automation platform to accelerate the development of their products. In their series A funding round, they raised $19 million from investors including Artis Ventures and Starlight Ventures. Locus Biosciences aims to create precision antimicrobials that avoid resistance mechanisms and address critical therapeutic areas such as resistant bacterial infections and the microbiome.